XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues        
Total revenues $ 797,519 $ 2,917,341 $ 2,618,313 $ 12,587,707
Total cost of revenues 552,287 1,648,023 1,846,333 7,133,271
Gross profit 245,232 1,269,318 771,980 5,454,436
Operating expenses:        
Selling, general and administrative 2,678,894 3,292,304 8,763,450 9,440,734
Research and development 913,031 836,123 2,762,040 2,796,171
Total operating expenses 3,591,925 4,128,427 11,525,490 12,236,905
LOSS FROM OPERATIONS (3,346,693) (2,859,109) (10,753,510) (6,782,469)
Interest income 36,295 26,783 84,972 34,108
Transaction costs allocated to warrant liabilities     (633,198)  
Unrealized gain (loss) on change in fair value of warrants classified as a liability 5,160,000 (278,400) 9,564,000 334,700
Unrealized loss on change in fair value of warrants classified as a liability - warrant modification     (394,000)  
Loss on issuance of warrants     (1,633,767)  
Other (expense) income, net (101) (3,469) (9,060) 6,396
Income (loss) before provision for income taxes 1,849,501 (3,114,195) (3,774,563) (6,407,265)
NET INCOME (LOSS) 1,849,501 (3,114,195) (3,774,563) (6,407,265)
Less: Net loss attributable to noncontrolling interest 30,295 14,429 78,785 52,470
NET INCOME (LOSS) attributable to Applied DNA Sciences, Inc. 1,879,796 (3,099,766) (3,695,778) (6,354,795)
Deemed dividend related to warrant modifications     (233,087)  
NET INCOME (LOSS) attributable to common stockholders $ 1,879,796 $ (3,099,766) $ (3,928,865) $ (6,354,795)
Net income (loss) per share attributable to common stockholders - basic (in dollars per share) $ 0.47 $ (4.80) $ (2.15) $ (9.85)
Net income (loss) per share attributable to common stockholders - diluted (in dollars per share) $ 0.47 $ (4.80) $ (2.15) $ (9.85)
Weighted average shares outstanding - basic (in shares) 4,014,261 645,426 1,830,882 645,426
Weighted average shares outstanding - diluted (in shares) 4,014,261 645,426 1,830,882 645,426
Product revenues        
Revenues        
Total revenues $ 246,644 $ 316,950 $ 947,086 $ 1,130,800
Total cost of revenues 230,188 368,902 853,034 1,103,843
Service revenues        
Revenues        
Total revenues 226,145 425,694 678,777 826,813
Clinical laboratory service revenues        
Revenues        
Total revenues 324,730 2,174,697 992,450 10,630,094
Total cost of revenues $ 322,099 $ 1,279,121 $ 993,299 $ 6,029,428